Precision BioSciences, Inc. - Common Stock (NQ:DTIL)

7.085 -0.065 (-0.91%)

Streaming Delayed Price Updated: 11:19 AM EDT, May 1, 2026 Add to My Watchlist

Price and Volume

Volume	79,587
Open	7.120
Bid (Size)	7.050 (100)
Ask (Size)	7.130 (100)
Prev. Close	7.150
Today's Range	6.845 - 7.165
52wk Range	3.530 - 8.770
Shares Outstanding	113,793,338
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026

April 30, 2026

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study

April 29, 2026

From Precision BioSciences, Inc.

Via Business Wire

Performance

YTD	+72.8%	+72.8%
1 Month	+28.8%	+28.8%
3 Month	+77.8%	+77.8%
6 Month	-17.7%	-17.7%
1 Year	+25.6%	+25.6%

More News

Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting

April 28, 2026

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

April 24, 2026

From Precision BioSciences, Inc.

Via Business Wire

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026

April 22, 2026

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries

April 15, 2026

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update

March 12, 2026

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program

March 11, 2026

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026

March 10, 2026

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026

March 09, 2026

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event

March 09, 2026

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis

March 02, 2026

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

February 18, 2026

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy

February 11, 2026

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy

January 12, 2026

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

December 23, 2025

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025

November 19, 2025

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants

November 10, 2025

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts

November 10, 2025

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Inc (NASDAQ:DTIL) Stock Falls After Q3 2025 Earnings and Revenue Miss ↗

November 03, 2025

Via Chartmill

Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update

November 03, 2025

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025

October 31, 2025

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025

October 14, 2025

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases

October 09, 2025

From Precision BioSciences, Inc.

Via Business Wire

Frequently Asked Questions

Is Precision BioSciences, Inc. - Common Stock publicly traded?

Yes, Precision BioSciences, Inc. - Common Stock is publicly traded.

What exchange does Precision BioSciences, Inc. - Common Stock trade on?

Precision BioSciences, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Precision BioSciences, Inc. - Common Stock?

The ticker symbol for Precision BioSciences, Inc. - Common Stock is DTIL on the Nasdaq Stock Market

What is the current price of Precision BioSciences, Inc. - Common Stock?

The current price of Precision BioSciences, Inc. - Common Stock is 7.085

When was Precision BioSciences, Inc. - Common Stock last traded?

The last trade of Precision BioSciences, Inc. - Common Stock was at 05/01/26 11:19 AM ET

What is the market capitalization of Precision BioSciences, Inc. - Common Stock?

The market capitalization of Precision BioSciences, Inc. - Common Stock is 806.23M

How many shares of Precision BioSciences, Inc. - Common Stock are outstanding?

Precision BioSciences, Inc. - Common Stock has 806M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.